New Strong Sell Stocks for July 22nd

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:

Belite Bio BLTE is a clinical stage biopharmaceutical drug development company which focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases. The Zacks Consensus Estimate for its current year earnings has been revised 59.1% downward over the last 60 days.

3D Systems DDD is a leading provider of 3D content-to-print solutions including 3D printers, print materials, on-demand custom parts services and 3D authoring solutions for professionals and consumers, worldwide. The Zacks Consensus Estimate for its current year earnings has been revised 17% downward over the last 60 days.

Annexon ANNX is a clinical-stage biopharmaceutical company which is engaged in developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The Zacks Consensus Estimate for its current year earnings has been revised almost 5.8% downward over the last 60 days.

View the entire Zacks Rank #5 List.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research